Skip to main content
Premium Trial:

Request an Annual Quote

Bioinformatics Credited With Helping Zeneca Make Rapid Progress

Premium

ALDERLEY EDGE, UK--Zeneca Pharmaceuticals here has credited bioinformatics with a significant role in the company's recent success. Investments in bioinformatics, gene discovery, and human genetics have helped the firm convert raw genomic data into drug targets quickly, resulting in a current slate of 87 development projects, including 26 for new compounds, and plans to increase the company's research output. The comments came from company officials, including CEO Tom McKillop and Richard Auty, research and development director, in a meeting last week with analysts and investors.

They also noted that Zeneca has been enhancing its genomics capabilities through collaborations with such organizations as Incyte Pharmaceuticals, Molecular Dynamics, and Oxford University. The company's research output is set to double over the next five years, Zeneca claimed.

Filed under

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.